Summary of COVID-19 gimsilumab studies

1. Criner et al., Anti-Granulocyte–Macrophage Colony–Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial

225 patient gimsilumab late treatment RCT: 10% higher mortality (p=0.71).
RCT 225 hospitalized COVID-19 patients showing no significant difference in mortality or clinical outcomes with the anti-GM-CSF monoclonal antibody gimsilumab compared to placebo.
May 2022, American J. Respiratory and Critical Care Medicine, https://www.atsjournals.org/doi/10.1164/rccm.202108-1859OC, https://c19p.org/criner